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X-ALD NBS Background Markov Model Background
Markov models seek to outline all the possible
states of a system and the transition paths between
those states. Within the context of X-ALD, the possible
states represent the health, disease, or treatment
status that X-ALD patients may have. In addition to the
phenotypic manifestations of the disease, there would
be health states for presymptomatic, healthy, bone
marrow transplant (a cALD treatment), and death.
Each health state is also defined by a cost and
benefit measure. For cost, we use dollars, and for
benefit, we use quality-adjusted-life-years (QALYs).
QALYs are a measure of disease burden that reflect
both the quality and quantity of life lived.
To begin parsing X-ALD’s various options for disease
progression, a simplified Markov model was created
which assumed that all presymptomatic newborns
eventually develop cALD, abnormal adrenal function, or
AMN. Both cALD and AMN are also assumed to always
include abnormal adrenal function. cALD can be
treated with bone marrow transplant while abnormal
adrenal function and AMN can be treated with various
symptom-specific treatments.
Question and Hypothesis
X-ALD Newborn Screening Simplified
Disease State Transition Model
Is newborn screening for X-linked adrenoleukodystrophy cost-effective?
Preliminary literature review and findings indicate ‘Yes.’ 
To what extent is not clearly known.
1. Validate proof of concept with simplified Markov model.
2. Undergo expert opinion review process to modify and expand Markov model
and continually assess validity of model assumptions.
3. Share findings with 30+ states that currently have no plans to screen X-ALD.
Next Steps
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X-linked adrenoleukodystrophy (X-ALD) is a genetic
disorder affecting one in 17,000 newborns and is
caused by a mutation in the ABCD1 gene. Although no
symptoms are shown in newborns, X-ALD
phenotypically manifests itself in children and adults in
three main ways: cerebral ALD (cALD), abnormal
adrenal function, and adrenomyeloneuropathy (AMN).
cALD affects 35-40% of young male patients and
results in a progressive deterioration of cognitive ability,
vision, hearing, and motor function. Untreated, it leads
to vegetative state followed by death. Abnormal
adrenal function affects almost all males and usually
presents within the first decade of life. Finally, AMN
affects 40-45% of all patients with typical onset in the
fourth decade of life. Although not life threatening,
AMN results in stiffness and tingling in feet, difficulty
walking, and issues with balance and strength.
X-ALD newborn screening is hypothesized to lead to
significantly earlier diagnosis for patients affected by
cALD and abnormal adrenal function—translating to
dramatically improved survival and markedly reduced
morbidity.
